Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCLL.L Regulatory News (CLL)

  • There is currently no data for CLL

Acquisition

26 Sep 2006 07:03

Cello Group plc26 September 2006 26 September 2006 CELLO ACQUIRES STRATEGY & RESEARCH CONSULTANCY SMT Cello Group plc ("Cello", AIM: CLL), the research and data led marketingservices group, has acquired SMT Consulting Limited ("SMT"), a leading strategyand research consultancy specialising in the fast growing market of business andcompetitive intelligence. Initial consideration consists of up to £6.2 millionwith further performance related consideration of up to £8.8 million. SMT's client base includes around 20% of the FTSE 100 companies and a number ofFortune 500 corporations in the areas of financial services, nuclear &utilities, telecoms and FMCG. It is based in Oxford, employs approximately 35people and also has an office in Shenzhen, China. The initial consideration consists of up to £6.2 million of which £4.2 millionis payable in cash and the balance satisfied by the issue of 1,542,480 newordinary shares. In addition, there are further performance related paymentsover the period to 31 December 2010. These payments are in a mixture of loannotes and new ordinary shares at Cello's discretion, with a maximum shareelement of 75%. In order to finance the cash element of the acquisition, Cello has entered intoa new £12 million committed three year banking facility. Following thetransaction, Cello has net debt of approximately £2 million. For the year to 30 April 2006, SMT had a turnover of £3.4 million and normalisedprofits before tax of £0.8 million. Net assets at 30 April 2006 were £0.7million including cash of £0.5 million. Application has been made to the London Stock Exchange for the new shares to beadmitted to AIM and it is expected that admission will take place by 29September 2006. Kevin Steeds, Cello Group's Chairman, said: "SMT is an exciting addition to the Cello Group, further strengthening ourupstream research and consulting offer. With its impressive client franchise inthe UK and Asia, SMT also helps accelerate the development of our internationaloffering." Enquiries: Cello GroupKevin Steeds, Executive Chairman 020 7812 8461 College HillAdrian Duffield/Ben Way 020 7457 2020 Notes to Editors (www.cellogroup.co.uk) Cello Group plc is a research and data led marketing services group that listedon AIM in November 2004. The Group's strategy is to create value for shareholders by building a portfolioof companies around three specialist platforms, each operating within adifferent niche of the marketing services sector: market research and planning,brand strategy and consultancy, and direct marketing, digital and databasemanagement. Each of Cello's three platforms has significant organic and acquisitive growthpotential; blue chip client relationships with a history of client loyalty;experienced, high quality management teams; and a track record of profitability. Cello Planning and Research * Insight Research Group - London, New York and Basel Insight is a specialist healthcare market research business that offers a broadrange of quantitative and qualitative research based solutions. Its clientsinclude GlaxoSmithKline, Novartis, AstraZeneca, Shire Pharmaceuticals,NovoNordisk, Boehringer Ingleheim, Lundbeck, Pfizer, Roche and Merck, Sharp andDohme. Insight recently acquired FML, a leading field force company. * Leapfrog Research and Planning - Windsor and New York Leapfrog is a leading consumer market research and planning consultancy offeringqualitative and quantitative research in the UK and internationally. It actsfor a number of blue chip clients including Tesco, GSK, BBC, Scottish Courage,Toyota, AA, RHM and Wyeth. * RS Consulting - London RS Consulting is a quantitative market research and business consultancy. Basedin London, the company employs approx 80 people across its three subsidiaries.Major clients include hp, Xerox, Sony, FedEx, Department of Work & Pensions,Cisco Systems, AXA, Yell, RBS, AON and BUPA. Cello Brand Consulting * Leith - Edinburgh and London Leith is the largest and most successful branding agency in Scotland. Theagency has been voted Scottish Agency of the Year for the last five years.Leith opened a London office in 2000 which has recently been integrated withFarm. Leith's major clients include Irn Bru, Scottish Executive, Standard LifeBank, Standard Life, Smile, ICI, FT and Goodfellas Pizza. * The Value Engineers - Beaconsfield TVE is a leading strategic brand consultancy focused on four core disciplines;branding, strategy, insight and innovation. Clients include Unilever,Carlsberg, Diageo, Sony Ericsson, ICI, Visa, BP, T-Mobile and Britvic. * TMI - Redditch Formed in 1978 TMI UK employs some 60 staff and is a leading provider oforganisational development and consultancy solutions to a range of blue chipclients including Toyota, hp, Metronet, Marks and Spencer, the Foreign andCommonwealth Office, National Express Group and Serco Solutions. Cello Response * Target Group - Cheltenham and Cirencester Target is the leading direct and database marketing consultancy specialising inthe "not-for-profit" and charity sector. The agency works for five of the top20 charities in the UK. Target is expanding into the "grey sector" of productsand services for older people for clients such as National Trust, Saga andWhich? Limited. Target has a leading database subsidiary, Talking Numbers and asuccessful print management operation, Target Direct Print. * Navigator Responsive Advertising - Edinburgh Navigator Responsive Advertising, Scotland's leading direct marketing agency,provides responsive communication solutions for a wide range of clientsincluding HBOS Group, De Vere Resort Ownership, ScottishPower, Abbey and RemyMartin. This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
14th May 20137:00 amRNSBoard Appointment
14th May 20137:00 amRNSAGM STATEMENT
10th May 20132:28 pmRNSAdditional Listing/TVR
23rd Apr 20137:00 amRNSHolding(s) in Company
19th Apr 20137:00 amRNSFace Launches Pulsar TRAC
12th Apr 20131:03 pmRNSAnnual Report and Accounts 2012
9th Apr 20137:00 amRNSDirector/PDMR Shareholding
2nd Apr 201312:44 pmRNSHolding(s) in Company
27th Mar 201310:00 amRNSHolding(s) in Company
20th Mar 20137:00 amRNSDirector/PDMR Shareholding
13th Mar 20137:00 amRNSPreliminary Results for the Year Ended 31 Dec 2012
1st Mar 20137:00 amRNSTotal Voting Rights
28th Jan 20137:00 amRNSPre-close trading update
28th Jan 20137:00 amRNSAcquisition of Mash Health
19th Dec 20129:50 amRNSHolding(s) in Company
14th Nov 20127:00 amRNSHealthcare Seminar
1st Oct 201212:29 pmRNSShare Option Grants
20th Sep 20129:09 amRNSDirector/PDMR Shareholding
19th Sep 20122:13 pmRNSDividend Timetable
19th Sep 20127:01 amRNSCello's Talking Taboos
19th Sep 20127:00 amRNSInterim Results 2012
3rd Sep 20128:30 amRNSNotice of Interim results
12th Jul 20122:21 pmRNSShare Option Grants
11th Jul 20127:00 amRNSTrading update
1st Jun 20127:00 amRNSTotal Voting Rights
24th May 20127:00 amRNSAdditional listing / TVR
16th May 201210:07 amRNSResult of AGM
15th May 20127:00 amRNSAGM Statement
1st May 20127:00 amRNSAdditional Listing
17th Apr 20127:00 amRNSAnnual Financial Report
27th Mar 20127:00 amRNSHolding(s) in Company
14th Mar 20127:00 amRNSDirector/PDMR Shareholding
13th Mar 20127:00 amRNSLaunch of CSR programme
13th Mar 20127:00 amRNSFinal Results
24th Jan 201212:59 pmRNSNotice of Results
23rd Jan 20127:01 amRNSYear end trading update
21st Dec 20117:00 amRNSDirectorate Change
19th Dec 20117:00 amRNSChange of Adviser
1st Nov 201111:30 amRNSHolding in Company
18th Oct 20117:00 amRNSHolding in Company
4th Oct 20117:00 amRNSDirector/PDMR Shareholding
21st Sep 201110:30 amRNSDirector/PDMR Shareholding
10th Aug 201110:37 amRNSNotice of Results
13th Jul 20117:00 amRNSDirector/PDMR Shareholding
6th Jul 20117:00 amRNSTrading update
14th Jun 20117:00 amRNSShare Option Grants
3rd Jun 201110:10 amRNSTotal Voting Rights
26th May 20117:00 amRNSAnalyst and investor teach-in
17th May 20111:23 pmRNSResult of AGM
17th May 20117:00 amRNSAGM Statement

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.